Compare AFLAC Incorporated (AFL) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs CVS Health Corp — how do they compare? AFLAC Incorporated trades at $122.08 (market cap $61.13B), while CVS Health Corp trades at $93.71 (market cap $122.36B). The key difference: CVS Health Corp is far larger — about 2× AFLAC Incorporated's market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| AFL | CVS | |
|---|---|---|
Market Cap | $61.13B | $122.36B |
Sector | Financials | Health |
52-Week High | $129.55 | $110.60 |
52-Week Low | $103.55 | $64.88 |
Enterprise Value | $71.08B | $184.71B |
Dividend Yield | 2% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $124.61, down 1.62% with recent earnings misses and bearish technical signals. The stock shows mixed fundamentals with a P/E of 13.44 and net income margin of 26.79%, though revenue declined to $17.36B in 2025. Recent news highlights Japan unit challenges and dividend reliability, with the company maintaining 43 consecutive years of dividend increases.
Outlook remains cautious with analyst consensus at Hold (56.24%) and price target of $117.60 below current levels. Key risks include foreign exchange headwinds and competitive pressures, while the dividend yield and strong cash flow provide support for income-focused investors amid near-term volatility.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
